Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B

• Published in: Alimentary pharmacology & therapeutics 2007-04, Vol.25 (8), p.891-898
• Main Authors: CHAN, H. L.‐Y., WONG, V. W.‐S., TSE, C.‐H., CHIM, A. M.‐L., CHAN, H.‐Y., WONG, G. L.‐H., SUNG, J. J.‐Y.
• Format: Article
• Language: English
• Subjects: Adenine - analogs & derivatives; Adenine - therapeutic use; Adult; Aged; Antiviral Agents - therapeutic use; Biological and medical sciences; Digestive system; Drug Resistance, Viral; Female; Gastroenterology. Liver. Pancreas. Abdomen; Hepatitis B virus; Hepatitis B, Chronic - drug therapy; Hong Kong; Human viral diseases; Humans; Infectious diseases; Lamivudine - therapeutic use; Male; Medical sciences; Middle Aged; Organophosphonates - therapeutic use; Pharmacology. Drug treatments; Treatment Outcome; Viral diseases; Viral hepatitis
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2007.03272.x

SUMMARY Aim To determine the factors affecting the virological response to adefovir dipivoxil (ADV) among patients with lamivudine resistant chronic hepatitis B. Methods Chronic hepatitis B virus (HBV) infected patients, who had virological relapse to lamivudine, were switched to ADV monotherapy. Results Twenty‐six patients were treated by ADV for 23 (12–41) months. At baseline, the median log HBV DNA was 7.70 (4.88–9.01) copies/mL. Six (23%) and 8 (31%) of patients had HBV DNA suppressed to below 1000 copies/mL at month 12 and the last follow‐up, respectively. On linear regression, patients who had higher HBV DNA at baseline and month 6 have higher HBV DNA at month 12. On Cox proportional hazard model, the hazard ratio for each log step increase in HBV DNA at baseline and month 6 for HBV DNA